PepGen: Stock Slides On FDA Study Hold - I'm Firmly On The Sidelines
Source: SeekingAlpha
2026-03-05 14:49:43 ET
Investment Overview
The stock of PepGen Inc. ( PEPG ) is down >20% in early trading today, after the company released its Q4 and full-year 2025 earnings, and shared the news that the FDA had placed a partial clinical hold on its FREEDOM2-DM1 Phase 2 multiple ascending dose ("MAD"), randomized, placebo-controlled clinical trial of candidate PGN-EDODM1 in patients with myotonic dystrophy type 1 ("DM1")....
Read the full article on Seeking Alpha
For further details see:
PepGen: Stock Slides On FDA Study Hold - I'm Firmly On The Sidelines
PepGen Inc.
NASDAQ: PEPG
PEPG Trading
1.26% G/L:
$5.62 Last:
257,268 Volume:
$5.45 Open:
PEPG Latest News
March 04, 2026 04:05:00 pm
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights
PEPG Stock Data
$378,802,714
40,177,150
1.23%
19
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
